background: The causative mechanisms of male infertility are still poorly understood. Mutations in the Methylenetetrahydrofolate reductase (MTHFR) gene have been shown to be involved in male infertility; however, other mechanisms of pathogenesis, like promoter hyper-methylation, could also play a role. Therefore, in this study we compared the methylation status of the promoter region of MTHFR in male patients with non-obstructive azoospermia (NOA) and obstructive azoospermia without anomalies of spermatogenesis. methods: DNA from peripheral blood (PB) samples of 50 patients with NOA and 50 fertile men (controls) as well as DNA from testicular biopsies of 32 patients with NOA and five patients with obstructive azoospemia, but normal spermatogenesis, were analyzed by Methylation Specific PCR amplification using primers that hybridize to the CpG island in the promoter region of MTHFR.
Introduction
Methylenetetrahydrofolate reductase (MTHFR) is a key regulatory enzyme involved in folate metabolism, DNA synthesis and remethylation reactions. MTHFR catalyses the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is the methyl donor for remethylation of homocysteine to methionine. Methionine is in turn converted to S-adenosylmethionine, a methyl donor used in many reactions whereby substrates such as DNA, RNA, hormones and lipids are methylated. It has been shown that MTHFR deficiency, in addition to folate deficiency, hinders the methylation of a wide variety of substrates, including proteins, DNA, RNA, and histones because of decreased methionine supply (Chen et al., 2001; Leopardi et al., 2006) . Mutations and some polymorphisms are known causes of low MTHFR enzymatic activity. Some polymorphisms, like the 677C!T substitution, have been widely studied and their inhibitory effects on MTHFR enzymatic activity (Frosst et al., 1995) as well as on remethylation are well known (Castro et al., 2006) . Reduced enzymatic activity due to MTHFR polymorphisms is a recognized predisposing factor of hyperhomocysteinemia (Austin et al., 2004) and many evidences implicate these polymorphisms in increased risk of cardiovascular disease, Alzheimer's disease, colon cancer, leukemia, diabetes mellitus, Down's syndrome and pregnancy complications (Carmel, 1996 (Carmel, , 1997 Chapman et al., 1998) .
Since abnormal DNA methylation of imprinted genes has been shown to be associated with oligozoospermia (Marques et al., 2008a) , spermatogenesis may be particularly vulnerable to changes in the methyl pool brought about by deficiency in MTHFR. In male mice, inactivation of MTHFR results in hyperhomocysteinemia and infertility with abnormal testicular histology characterized by absence of germinal cells and spermatogenesis arrest (Kelly et al., 2005) . These findings are in favor of a role of MTHFR in normal spermatogenesis and suggest that its deregulation could be involved in male infertility. However, studies on the role of MTHFR polymorphisms in male infertility have produced contradictory results. Some works have shown a significant statistical correlation between MTHFR polymorphisms and male infertility (Park et al., 2005; Singh et al., 2005) , whereas others did not find any significant association (Bezold et al., 2001; Paracchini et al., 2006) . These discrepancies could be explained by the fact that, in some patients with male infertility, the reduction of MTHFR activity may be linked to other modifications, like, for instance, abnormal methylation of its promoter region. Indeed, epigenetic modifications at several genes, such as methylation of the promoter region and the subsequent down-regulation of gene expression, have been shown to act similarly and in some cases in parallel to genetic mutations in a number of pathologies (Baylin and Herman, 2000) . For these reasons, we decided to assess the methylation status of the promoter region of MTHFR in infertile patients with non-obstructive azoospermia (NOA).
Materials and Methods

Patients, blood and tissue collection
This study was conducted from January 2008 till December 2008 at the Sarem Cell Research Center (SCRC), Iran. The informed consent of all the patients was obtained and the study was approved by the local ethical committee. Analysis of the methylation status of MTHFR promoter was carried out on DNA extracted from peripheral blood (PB) and testicular biopsies (T). DNA was isolated from PB of 50 patients with NOA (PB-p group) and 50 fertile men (controls) (PB-c group) using the rapid 'salting out' method as described (Lahiri et al., 1992) . DNA from testicular biopsy samples of 32 patients with NOA (T-p group) and five patients (T-c group) with obstructive azoospemia but normal spermatogenesis, as verified by histopathological examination of the samples, was isolated using the High Pure PCR Template Preparation Kit (Roche Applied Science) as recommended by the manufacturer.
Sodium bisulfite treatment
Briefly, 10 ml DNA from PB or testis was denatured with 0.2 mol/l NaOH for 10 min at 378C in 50 ml total volume. About 30 ml of 10 mmol/l hydroquinone and 520 ml of 3.5 mol/l sodium bisulfite (pH 5.0) were added. DNA samples were incubated under mineral oil at 508C for 16 h. Samples were then purified using Qiagen DNA purification columns. Recovered samples were desulfonated in 0.3 M NaOH for 5 min at room temperature. After ethanol precipitation, DNA was dissolved in 40 ml water and used immediately for PCR amplification or stored at 2208C.
Methylation-specific PCR analysis
Analysis of the DNA methylation status of the CpG island located within the promoter region of MTHFR was carried out using MethylationSpecific PCR (MSP) amplification. Primers were designed using Methprimer (Li and Dahiya, 2002) to distinguish methylated and unmethylated DNA after bisulphate treatment of the template and had the following sequences:
0 -CAAAAAACTAA TAAAAAACCAACAAA-3. MSP was performed in a total volume of 25 ml. PCR reactions for both primer sets contained 12.65 ml DDW, 2 mM MgCl2, 0.1 mM dNTP, 2.5 ml 10Â PCR buffer, 3 ml (100 ng) DNA, 0.5 mM of each primer, 0.5 ml Taq DNA polymerase (Cinnagen Iran). An initial denaturing step at 948C for 5 min was followed by 40 cycles at 948C for 40 s, 648C for MTHFRmet primers (628C for MTHFRunmet primers) for 40 s and 728C for 1 min and a final extension at 728C for 5 min.
Amplified fragments were separated by electrophoresis on 8% nondenaturing polyacrylamide gel electrophoresis and stained with ethidium bromide.
One control PB DNA sample was methylated using Sss1 methyltransferase (New England BioLabs) according to the manufacturer's protocol and used as methylated, positive control for MSP reactions.
Statistical analysis
The observed epigenotype frequencies (i.e. methylated, unmethylated or methylated/unmethylated) were compared between groups using the Mann-Whitney test. P-values ,0.05 were considered statistically significant.
Results
In order to determine the DNA methylation status at MTHFR promoter region in patients with NOA, we first performed MSP on DNA from PB samples of 50 infertile patients with NOA and 50 fertile controls (Table I and Fig. 1C and D) . The unmethylated allele was detected in all patients (PB-p) and controls (PB-c), whereas the methylated allele was amplified in only 15 patients (30%) and 9 controls (18%). This difference in frequency was not statistically significant (P ¼ 0.16).
We then performed the same analysis on DNA from testicular biopsy samples of 32 patients with NOA (T-p) and five infertile controls with obstructive azoospermia (T-c) (Table II and Fig. 1A and B) . In testicular tissues, the methylated allele was detected in 53% of the NOA patients in addition to the unmethylated one. Conversely, in the control group, both alleles were unmethylated. These results indicate that, in testis, the promoter region of MTHFR is hyper-methylated in NOA patients in comparison to controls (P ¼ 0.03). 
Discussion
In this work we show that, in infertile patients with NOA, the promoter of MTHFR has aberrant methylation in testis, but not in blood samples. In controls with obstructive azoospermia and normal spermatogenesis, only the unmethylated allele was detected, which is in agreement with previous reports that demonstrated the presence of de novo methylation reprogramming as early as blastocyst stage (Santos and Dean, 2004) . Animal model studies suggest that MTHFR plays a critical role in spermatogenesis due to its exceptionally high activity in adult testis in comparison to other organs (Chen et al., 2001) . Detection of only the unmethylated allele in controls is in agreement with the high activity of this gene in adults with normal spermatogenesis.
Epigenetic silencing is achieved not only through DNA methylation but also by many other DNA, chromatin and RNA modifications (Shilatifard, 2006; Chuang and Jones, 2007) . Nevertheless, DNA methylation of the promoter sequence of MTHFR appears to be a good candidate for down-regulation of MTHFR expression as indicated by this work and also by a recent, large case -control study in patients with lung cancer (Vaissiere et al., 2009 ). Interestingly, in both studies, hyper-methylation is observed only in specific tissues (testis in this study and lung in the previous work), consistent with the hypothesis that aberrant methylation can be disease-specific and gene-specific. Furthermore, our finding that hyper-methylation of the promoter region of MTHFR is present only in testis and not in PB samples indicates that it is not due to a general methylation defect. Similarly, a previous study on infertile males with hypo-or azoospermia reported that the methylation pattern was specifically perturbed only in some imprinted genes and was not due to general hypo-or hypermethylation (Marques et al., 2008b) .
Hyper-methylation of the promoter region has been shown to influence the expression of several genes. For instance, Pike and coworkers (Pike et al., 2008) reported significant hyper-methylation of the 5 0 UTR of 12 genes, including MTHFR, in diffuse large B-cell lymphoma. Moreover, they found that hyper-methylated CpG islands are frequently proximal to genes that are expressed at low or undetectable levels in these tumors. Therefore, we hypothesize that the hyper-methylation found at the promoter region of MTHFR in this study might down-regulate MTHFR expression and as a consequence reduce its enzymatic activity. MTHFR deregulation, in turn, may play a role in the development of azoospermia in NOA patients. This hypothesis is supported by the finding that changes in DNA methylation pattern in mouse male germ cells can result in absence of vas deference or azoospermia (Doerksen et al., 2000) .
In conclusion, we propose that deregulation of MTHFR expression in male infertility might be due to at least two mechanisms: gene mutation (as reported by others) and aberrant promoter methylation (this study). Since MTHFR is a crucial enzyme within the folate pathway, treatment with folate should be assessed as a therapeutic approach in clinical studies where its effects are compared in azoospemic patients with and without aberrant methylation of the promoter of MTHFR.
